Evidence map›Paper›PMID 42594167›Full record

ReviewCirculation research2026

Platelet Reactivity and Sex Differences: Clinical Implications for Women.

Anu Aggarwal, Tessa J Barrett, Puja K Mehta, Michael C Honigberg, Judith M E M Cosemans, Wendy A Goodman, Niti R Aggarwal, Michael Holinstat, Leslie Cho, Scott J Cameron and 1 more

Abstract readReview
In one paragraph

Review in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anu AggarwalCleveland Clinic Research, Heart, Blood, and Kidney Research, Cleveland Clinic Foundation, OH (A.A., S.J.C.).ORCID 0000-0002-2357-3827
Tessa J BarrettLeon H. Charney Division of Cardiology, Department of Medicine, Cardiovascular Research Center, New York University Grossman School of Medicine (T.J.B.).ORCID 0000-0003-0751-1578
Puja K MehtaEmory Women's Heart Center and Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA (P.K.M.).ORCID 0000-0002-5678-812X
Michael C HonigbergProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA (M.C.H.).ORCID 0000-0001-8630-5021
Judith M E M CosemansDepartment of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, the Netherlands (J.M.E.M.C.).ORCID 0000-0001-7429-0109
Wendy A GoodmanDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH (W.A.G.).ORCID 0000-0002-6864-0384
Niti R AggarwalDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (N.R.A.).
Michael HolinstatDepartment of Pharmacology (M.H.), University of Michigan Medical School, Ann Arbor.ORCID 0000-0001-5100-1933
Leslie ChoHeart Vascular and Thoracic Institute, Department of Cardiovascular Medicine, Section of Preventive Cardiology, Cleveland Clinic Foundation, OH (L.C.).ORCID 0000-0002-1190-1774
Scott J CameronCleveland Clinic Research, Heart, Blood, and Kidney Research, Cleveland Clinic Foundation, OH (A.A., S.J.C.).ORCID 0000-0002-9616-1540
ACC Cardiovascular Disease in Women Committee

Funding

Platelets as Biosensors and Mediators of Aortic Aneurysm GrowthR01HL158801 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI CAMERON, SCOTT JAMES · 2021 to 2025
$2.5M
CD37 as a Regulator of Platelet Patho(Physiological) ResponsesR01HL167917 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Tessa Barrett · 2023 to 2026
$2.3M
Platelets as therapeutic and diagnostic entity in fibromuscular dysplasiaK99HL181079 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Anu Aggarwal · 2025 to 2026
$238k
NHLBI NIH HHS K99 HL181079NHLBI NIH HHS R01 HL158801NHLBI NIH HHS R01 HL167917
6 · The paper itself

Abstract

Platelets are central to hemostasis and thrombosis. Excessive platelet activation contributes to arterial thrombotic events, including myocardial infarction, ischemic stroke, and complications of peripheral artery disease, whereas excessive platelet inhibition increases bleeding risk. Antiplatelet therapy remains a cornerstone of secondary prevention in atherosclerotic and thrombotic cardiovascular diseases, yet current treatment paradigms do not fully account for biological heterogeneity in platelet function, including differences related to sex, age, hormonal status, and disease context. This state-of-the-art review examines current antiplatelet strategies, fundamental mechanisms of signal transduction, clinical indications, and limitations of preclinical and clinical studies, with a focus on sex-specific considerations and opportunities for personalized antiplatelet therapy. Aspirin and P2Y

Indexed as

Blood PlateletsPlatelet ActivationPlatelet Aggregation InhibitorsSex CharacteristicsThrombosisAnimalsFemaleHemostasisHumansMaleSex FactorsPlatelet Aggregation Inhibitorsbiologyhemostasisleukocytesplatelet activationthrombosis

Identifiers

PMID42594167
PMCPMC13479948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.